Skip to content

Observational Study to Evaluate the Relationship Between Ketonemia and Renal Function in the Diabetic Patient

Observational Study to Evaluate the Relationship Between Ketonemia and Renal Function in the Diabetic Patient

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03859817
Acronym
TAKEN-DKD
Enrollment
68
Registered
2019-03-01
Start date
2019-04-16
Completion date
2021-12-31
Last updated
2021-09-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Nephropathy Type 2

Brief summary

A multicentre real life study is proposed. The study has as its goal primary to compare the levels of ketonemia measured in patients with albuminuria and patients normo albuminurici to evaluate a possible correlation between ketone level and alteration of renal function in the diabetic patient, comparing the eGFR values of patients with ketonemia high and of patients with low ketonemia. In these patients, the lack of insulin causes one imbalance between ketogenesis and ketolysis, with increased production and reduced body clearance ketones. Several studies explore the effects of ketone bodies on cell function and lesions diabetic complications: ketonemia induces oxidative stress and increases the risk and the progression of complications, moreover, the increase in ketone levels may have pro-inflammatory effects. However, ketonemia levels between normal and DKA are poorly studied and their effects are still unknown. It is hypothesized that * in diabetic patients with DKD the level of ketones may be high; * Increased ketone levels may promote an alteration of renal function. We want to evaluate the relationship between ketone levels and renal function, because the kidneys, as well as the heart, are among the main organs in which the ketone bodies are oxidized to produce energy and DKD has a high morbidity and mortality in diabetes. The main objectives for being able to demonstrate the hypothesis in question are: * Evaluate the level of ketones in albuminurate patients with diabetes and in patients with renal function altered; * Evaluate the association between ketone level and decline of renal function in the diabetic patient e therefore the impact of ketonemia on the progression of renal function loss.

Detailed description

At the beginning and during the course of the study the glycemic and ketone index obtained by the homologous blood glucose monitoring will be evaluated. During the study, prognostic biomarkers (sP2X7R, KIM-1, sTNFR1, 11-dehydro-tromoxane B2 and 6-keto-prostaglandin-F-1a (PGF1α)), which are presumed to play an important role in inflammatory renal diseases, will also be measured in diabetic subject, in addition to the traditional marker that is the urinary albumin. Step 1. Visit Baseline: blood sampling and collection of a urinary sample, evaluation proteinuria, GFR and blood and urinary ketones Step 2. Visit at 6 months: blood collection and collection of a urinary sample, evaluation proteinuria, GFR and blood and urinary ketones Step 3. Visit at 12 months: blood collection and collection of a urinary sample, evaluation proteinuria, GFR and blood and urinary ketones. The study involves the enrollment of T1D and T2D subjects in diabetic nephropathy. The study involves the enrollment of T1D and T2D subjects in diabetic nephropathy A timetable will be prepared for the surgeries during the which the diabetic subject will be informed about the study protocol in question and will provide eventual informed consent to entry into the study, blood sampling and urinary sample collection. However, the analysis will be above all exploratory and will allow to foresee possible studies future properly sized.

Interventions

OTHERComparison of eGFR values and ketonemia in diabetic patients

To verify if there is a correlation between the level of ketones and an alteration of the renal function in the diabetic patient, the values of the prognostic markers indicated in the protocol and the data downloaded by the glucometers will be evaluated in addition to the blood tests of the patients

Sponsors

University of Milan
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

Presence of albuminuria (≥30 mg / 24h) * Adult and male patients of age * Diagnosis of type 1 or type 2 diabetes according to the ADA diagnostic criteria * Presence of the disease for at least five years * HbA1c≥7% * Written informed consent of the patient and / or parents or legal guardian

Exclusion criteria

Chronic end-stage renal disease (CKD5) * Current or previous treatments with immunosuppressants (with the exception of topical steroids ed inhalers) * Participation in other clinical studies * Significant disease other than diabetes found in the two weeks prior to the first visit * Neurological or psychiatric diseases, hemoglobinopathies, liver diseases, cancer, cystic fibrosis, renal failure, malabsorption syndromes * Abuse of alcohol and drugs * HIV or hepatitis * Pregnant or lactating women (β-HCG urinary should be evaluated before each visit) * Presence of serious diseases or conditions of the patient considered unsuitable by the Investigator for be able to include it in the study * Poor understanding by the patient of spoken and written Italian

Design outcomes

Primary

MeasureTime frameDescription
Variations in albuminuria and albumin / creatinine ratio in urine (UACR)12 monthsimmunoturbidimetric method
Variations of the eGFR (CKD-EPI formula)12 monthsCKD-EPI formula
Variations in ketone levels12 monthsmonitoring ketones in capillary and urinary samples

Secondary

MeasureTime frameDescription
Variations of tubular function markers (sP2X7R, KIM-1, sTNFR1)12 monthsenzyme immunoassay (ELISA)
Variations of markers of glomerular function (11-dehydro-tromoxane B2 and 6-keto-prostaglandin- F-1a (PGF1α))12 monthsenzyme immunoassay (ELISA)
Changes in glycated hemoglobin (HbA1c)12 monthscapillary electrophoresis

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026